Vazquez Chris 4

4 · BIODESIX INC · Filed Feb 23, 2026

AI-generated summary of this filing

Updated Feb 24, 2026

Biodesix (BDSX) Chief Accounting Officer Chris Vazquez Sells 211 Shares

What Happened

Chris Vazquez, Chief Accounting Officer of Biodesix (BDSX), had 563 restricted stock units (RSUs) convert to 563 shares on Feb 20, 2026 (reported as an exercise/conversion of a derivative). Following the vesting, 211 shares were sold in the open market on Feb 23, 2026 for a weighted average price of $12.78, generating proceeds of $2,696. The sale was an automatic withholding/sale to cover taxes on the RSU vesting.

Key Details

Transaction dates: RSU conversion/exercise (derivative) on 2026-02-20; sale on 2026-02-23.
Sale: 211 shares sold at a weighted average price of $12.78; proceeds $2,696. Reported per-share sale prices ranged from $12.58 to $13.16 (weighted avg shown).
RSU conversion: 563 RSUs converted to 563 shares (reported as derivative exercise/conversion). A disposal entry at $0.00 reflects the conversion/cancellation of the RSUs upon vesting.
Shares owned after the transactions: not disclosed in the Form 4.
Footnotes of note:
- F1: Each RSU equals a contingent right to one share.
- F2/F3: Shares were sold automatically to cover taxes; sale price is a weighted average; detailed per-trade breakdown is available on request.
- F4: All share numbers reflect a 1-for-20 reverse split effective Sept 15, 2025.
- F5: The RSUs vest in four equal annual installments starting Feb 20, 2025, subject to continued service and have no expiration.
Filing: Form 4 filed Feb 23, 2026 (appears timely relative to the reported dates).

Context

This was a routine, tax-withholding sale tied to RSU vesting (not an outright discretionary sell by the insider). The derivative activity reflects RSU conversion to common shares (no cash exercise). Such automatic sales to cover withholding are common and do not necessarily indicate the insider's view on the stock.

Form 4

Period: 2026-02-20

Chief Accounting Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-20+563→ 1,797 total
Sale
Common Stock
[F2][F3]
2026-02-23$12.78/sh−211$2,696→ 1,586 total
Exercise/Conversion
Restricted Stock Units
[F1][F4][F5]
2026-02-20−563→ 1,689 total
→ Common Stock (563 underlying)

Footnotes (5)

[F1]Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
[F2]These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
[F3]The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.
[F5]These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Signature

/s/ Robin H. Cowie as Attorney-in-Fact for Chris Vazquez|2026-02-23

1 file